Four years in the making, AbbVie and Calibr provide first look into ‘switchable’ CAR-T program
In 2018, AbbVie and Calibr — a branch of Scripps Research Institute — announced a partnership for a next-gen CAR-T program, then still in its preclinical stages.
Four years later, that program has produced its first in-human data. At a CAR-T conference in Boston, Calibr gave an early glimpse at how its “switchable” CAR-Ts are working in patients with B cell blood cancers. Out of nine patients, six went into complete remission, and one more had a partial response. The first patient who had a complete response saw their disease return after nearly one year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.